140 related articles for article (PubMed ID: 36788083)
21. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
Sobanko JF; Okman J; Miller C
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
[TBL] [Abstract][Full Text] [Related]
22. Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions.
Bartoš V; Pokorný D; Zacharová O; Haluska P; Doboszová J; Kullová M; Adamicová K; Péč M; Péč J
Acta Dermatovenerol Alp Pannonica Adriat; 2011 Jun; 20(2):67-75. PubMed ID: 21993704
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Molecular Genetics of Basal Cell Carcinoma.
Pellegrini C; Maturo MG; Di Nardo L; Ciciarelli V; Gutiérrez García-Rodrigo C; Fargnoli MC
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165358
[TBL] [Abstract][Full Text] [Related]
24. Novel PTCH1 and concurrent TP53 mutations in four patients with numerous non-syndromic basal cell carcinomas: The paradigm of oncogenic synergy.
Dasgeb B; Pajouhanfar S; Jazayeri A; Schoenberg E; Kumar G; Fortina P; Berger AC; Uitto J
Exp Dermatol; 2022 May; 31(5):736-742. PubMed ID: 34862824
[TBL] [Abstract][Full Text] [Related]
25. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
Ionescu DN; Arida M; Jukic DM
Arch Pathol Lab Med; 2006 Jan; 130(1):45-51. PubMed ID: 16390237
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions.
Urman NM; Mirza A; Atwood SX; Whitson RJ; Sarin KY; Tang JY; Oro AE
PLoS One; 2016; 11(12):e0168031. PubMed ID: 28030567
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.
Reifenberger J; Wolter M; Knobbe CB; Köhler B; Schönicke A; Scharwächter C; Kumar K; Blaschke B; Ruzicka T; Reifenberger G
Br J Dermatol; 2005 Jan; 152(1):43-51. PubMed ID: 15656799
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas.
Boaventura P; Pereira D; Mendes A; Batista R; da Silva AF; Guimarães I; Honavar M; Teixeira-Gomes J; Lopes JM; Máximo V; Soares P
J Dermatol Sci; 2014 Jan; 73(1):31-9. PubMed ID: 24091058
[TBL] [Abstract][Full Text] [Related]
29. SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas.
Kim AL; Back JH; Chaudhary SC; Zhu Y; Athar M; Bickers DR
J Invest Dermatol; 2018 Aug; 138(8):1716-1725. PubMed ID: 29550418
[TBL] [Abstract][Full Text] [Related]
30. Advanced basal cell carcinoma.
Wollina U; Tchernev G
Wien Med Wochenschr; 2013 Aug; 163(15-16):347-53. PubMed ID: 23589318
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Basal Cell Carcinoma of the Skin: A Comprehensive Literature Review, Including Advances in Molecular Therapeutics.
Bisceglia M; Panniello G; Galliani CA; Centola M; D'Errico MM; Minenna E; Tucci FA; Ben-Dor DJ
Adv Anat Pathol; 2020 Sep; 27(5):331-353. PubMed ID: 32618586
[TBL] [Abstract][Full Text] [Related]
32. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin.
Makinodan E; Marneros AG
Exp Dermatol; 2012 Nov; 21(11):847-52. PubMed ID: 23163650
[TBL] [Abstract][Full Text] [Related]
33. Distinct non-clock-like signatures of the basal cell carcinomas from three sisters with a lethal Gorlin-Goltz syndrome.
Ye L; Wang L; Peng K; Fang O; Tian Z; Li C; Fu X; Chen Q; Chen J; Luan J; Zhang Z; Zhang Q
BMC Med Genomics; 2022 Aug; 15(1):172. PubMed ID: 35932013
[TBL] [Abstract][Full Text] [Related]
34. Advanced basal cell carcinoma: What dermatologists need to know about diagnosis.
Krakowski AC; Hafeez F; Westheim A; Pan EY; Wilson M
J Am Acad Dermatol; 2022 Jun; 86(6S):S1-S13. PubMed ID: 35577405
[TBL] [Abstract][Full Text] [Related]
35. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
36. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
37. AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.
Kim AL; Back JH; Zhu Y; Tang X; Yardley NP; Kim KJ; Athar M; Bickers DR
Cancer Prev Res (Phila); 2016 Oct; 9(10):794-802. PubMed ID: 27388747
[TBL] [Abstract][Full Text] [Related]
38. Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor-Resistant Basal Cell Carcinoma Cells via Targeting EGFR-MAPK-Akt and Hedgehog Signaling.
Dheeraj A; Rigby CM; O'Bryant CL; Agarwal C; Singh RP; Deep G; Agarwal R
Photochem Photobiol; 2017 Jul; 93(4):999-1007. PubMed ID: 28120452
[TBL] [Abstract][Full Text] [Related]
39. Genomic analysis of metastatic cutaneous squamous cell carcinoma.
Li YY; Hanna GJ; Laga AC; Haddad RI; Lorch JH; Hammerman PS
Clin Cancer Res; 2015 Mar; 21(6):1447-56. PubMed ID: 25589618
[TBL] [Abstract][Full Text] [Related]
40. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
